Sodium glucose Cotransporter-2 inhibitor Empagliflozin increases antioxidative capacity and improves renal function in Diabetic rats H Yaribeygi, MA Hemmati, F Nasimi, M Maleki, T Jamialahmadi, I Reiner, ... Journal of Clinical Medicine 12 (11), 3815, 2023 | 11 | 2023 |
Empagliflozin alleviates diabetes-induced cognitive impairments by lowering nicotinamide adenine dinucleotide phosphate oxidase-4 expression and potentiating the antioxidant … H Yaribeygi, MA Hemmati, F Nasimi, R Pakdel, T Jamialahmadi, ... Behavioural Brain Research 460, 114830, 2024 | 5 | 2024 |
Using new technologies to analyze gut microbiota and predict cancer risk MA Hemmati, M Monemi, S Asli, S Mohammadi, B Foroozanmehr, ... Cells 13 (23), 1987, 2024 | 4 | 2024 |
Modulating effects of crocin on lipids and lipoproteins: Mechanisms and potential benefits H Yaribeygi, M Maleki, F Rashid-Farrokhi, PR Abdullahi, MA Hemmati, ... Heliyon, 2024 | 4 | 2024 |
Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies M Eslami, A Safaripour, SZ Banihashemian, S Nikjoo Niaragh, ... Microorganisms 13 (2), 295, 2025 | | 2025 |
Sodium-glucose cotransporter 2 inhibitors and renin-angiotensin-aldosterone system, possible cellular interactions and benefits B Forouzanmehr, AH Hedayati, E Gholami, MA Hemmati, M Maleki, ... Cellular Signalling 122, 111335, 2024 | | 2024 |
GLP-1 mimetics and diabetic ketoacidosis: possible interactions and clinical consequences B Forouzanmehr, MA Hemmati, SL Atkin, T Jamialahmadi, H Yaribeygi, ... Naunyn-Schmiedeberg's Archives of Pharmacology, 1-12, 2024 | | 2024 |